{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:39:49Z","timestamp":1788982789524,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013254","name":"National College Students Innovation and Entrepreneurship Training Program","doi-asserted-by":"publisher","award":["G201810284157"],"award-info":[{"award-number":["G201810284157"]}],"id":[{"id":"10.13039\/501100013254","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673436"],"award-info":[{"award-number":["81673436"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872877"],"award-info":[{"award-number":["81872877"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903620"],"award-info":[{"award-number":["81903620"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91853109"],"award-info":[{"award-number":["91853109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20190306"],"award-info":[{"award-number":["BK20190306"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.intimp.2020.106206","type":"journal-article","created":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T11:27:43Z","timestamp":1580556463000},"page":"106206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Andrographolide potentiates PD-1 blockade immunotherapy by inhibiting COX2-mediated PGE2 release"],"prefix":"10.1016","volume":"81","author":[{"given":"Wen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingdong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.intimp.2020.106206_b0005","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"issue":"49","key":"10.1016\/j.intimp.2020.106206_b0010","doi-asserted-by":"crossref","first-page":"80262","DOI":"10.18632\/oncotarget.12918","article-title":"Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROS-mediated NF-kappaB signaling and NLRP3 inflammasome activation","volume":"7","author":"Peng","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.intimp.2020.106206_b0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.intimp.2014.03.015","article-title":"Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1\/Th17 response","volume":"20","author":"Liu","year":"2014","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106206_b0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.apsb.2016.02.002","article-title":"Andrographolide sulfonate ameliorates lipopolysaccharide-induced acute lung injury in mice by down-regulating MAPK and NF-kappaB pathways","volume":"6","author":"Peng","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.intimp.2020.106206_b0025","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.intimp.2012.09.002","article-title":"Water-soluble andrographolide sulfonate exerts anti-sepsis action in mice through down-regulating p38 MAPK, STAT3 and NF-kappaB pathways","volume":"14","author":"Guo","year":"2012","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106206_b0030","doi-asserted-by":"crossref","first-page":"972","DOI":"10.4161\/auto.28374","article-title":"Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer","volume":"10","author":"Guo","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.intimp.2020.106206_b0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcp.2016.09.024","article-title":"Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression","volume":"121","author":"Wang","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2020.106206_b0040","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2020.106206_b0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nm.3831","article-title":"Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection","volume":"21","author":"Chen","year":"2015","journal-title":"Nat. Med."},{"issue":"7533","key":"10.1016\/j.intimp.2020.106206_b0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature14034","article-title":"Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance","volume":"517","author":"Kurtova","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.106206_b0055","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1602023113","article-title":"PGE2 induced in and released by dying cells functions as an inhibitory DAMP","author":"Hangai","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"26","key":"10.1016\/j.intimp.2020.106206_b0060","doi-asserted-by":"crossref","first-page":"8070","DOI":"10.1073\/pnas.1424355112","article-title":"COX\/mPGES-1\/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset","volume":"112","author":"Larsson","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"242","key":"10.1016\/j.intimp.2020.106206_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008455","article-title":"COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models","volume":"6","author":"Xu","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2020.106206_b0070","first-page":"21","article-title":"Phenotypic and functional characterization of cytotoxic T lymphocytes by flow cytometry, Methods in molecular biology","volume":"1186","author":"Popescu","year":"2014","journal-title":"(Clifton, N.J.)"},{"key":"10.1016\/j.intimp.2020.106206_b0075","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jneuroim.2017.11.003","article-title":"Andrographolide - a promising therapeutic agent, negatively regulates glial cell derived neurodegeneration of prefrontal cortex, hippocampus and working memory impairment","volume":"313","author":"Das","year":"2017","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.106206_b0080","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s13046-018-0926-9","article-title":"Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway","volume":"37","author":"Peng","year":"2018","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"9","key":"10.1016\/j.intimp.2020.106206_b0085","doi-asserted-by":"crossref","first-page":"e106748","DOI":"10.1371\/journal.pone.0106748","article-title":"Discovery and validation of new potential biomarkers for early detection of colon cancer","volume":"9","author":"Sole","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2020.106206_b0090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","article-title":"A CXCL1 paracrine network links cancer chemoresistance and metastasis","volume":"150","author":"Acharyya","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.106206_b0095","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3389\/fimmu.2018.02159","article-title":"The role of CXC chemokine receptors 1\u20134 on immune cells in the tumor microenvironment","volume":"9","author":"Susek","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2020.106206_b0100","doi-asserted-by":"crossref","first-page":"e1001162","DOI":"10.1371\/journal.pbio.1001162","article-title":"Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor","volume":"9","author":"Toh","year":"2011","journal-title":"PLoS Biol."},{"issue":"21","key":"10.1016\/j.intimp.2020.106206_b0105","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.intimp.2020.106206_b0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1479-5876-4-48","article-title":"Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment","volume":"4","author":"Lewis","year":"2006","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.106206_b0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10555-006-7886-9","article-title":"Matrix metalloproteinases and tumor metastasis","volume":"25","author":"Deryugina","year":"2006","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.intimp.2020.106206_b0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nri3790","article-title":"Clinical blockade of PD1 and LAG3\u2013potential mechanisms of action","volume":"15","author":"Nguyen","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2020.106206_b0125","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"23","key":"10.1016\/j.intimp.2020.106206_b0130","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2020.106206_b0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-016-0163-8","article-title":"5-Fluorouracil upregulates cell surface B7\u2013H1 (PD-L1) expression in gastrointestinal cancers","volume":"4","author":"Van Der Kraak","year":"2016","journal-title":"J. Immunotherap. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2020.106206_b0140","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","article-title":"Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors","volume":"3","author":"Thommen","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2020.106206_b0145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","article-title":"Resistance to PD1\/PDL1 checkpoint inhibition","volume":"52","author":"O'Donnell","year":"2017","journal-title":"Cancer Treatm. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2020.106206_b0150","doi-asserted-by":"crossref","first-page":"e000375","DOI":"10.1136\/esmoopen-2018-000375","article-title":"Phase Ib\/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer","volume":"3","author":"Fumet","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.intimp.2020.106206_b0155","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/bs.ai.2015.12.005","article-title":"Combinatorial cancer immunotherapies","volume":"130","author":"Hellmann","year":"2016","journal-title":"Adv. n Immunol."},{"issue":"20","key":"10.1016\/j.intimp.2020.106206_b0160","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","article-title":"Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors","volume":"20","author":"Wainwright","year":"2014","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2020.106206_b0165","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14740338.2017.1300656","article-title":"EGFR TKI combination with immunotherapy in non-small cell lung cancer","volume":"16","author":"Ahn","year":"2017","journal-title":"Expert Opin. Drug Safety"},{"key":"10.1016\/j.intimp.2020.106206_b0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2018.01.024","article-title":"PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements","volume":"118","author":"Yoneshima","year":"2018","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"9","key":"10.1016\/j.intimp.2020.106206_b0175","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2020.106206_b0180","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1078-0432.CCR-16-1163","article-title":"PD-1\/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors","volume":"23","author":"Seifert","year":"2017","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"14","key":"10.1016\/j.intimp.2020.106206_b0185","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1073\/pnas.1602023113","article-title":"PGE2 induced in and released by dying cells functions as an inhibitory DAMP","volume":"113","author":"Hangai","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"22","key":"10.1016\/j.intimp.2020.106206_b0190","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1111\/bph.13331","article-title":"Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?","volume":"172","author":"O'Callaghan","year":"2015","journal-title":"British J. Pharmacol."},{"key":"10.1016\/j.intimp.2020.106206_b0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.canlet.2016.12.031","article-title":"Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2\/PGE2\/STAT3 axis","volume":"389","author":"Tong","year":"2017","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.intimp.2020.106206_b0200","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1073\/pnas.1612920114","article-title":"COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells","volume":"114","author":"Prima","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.intimp.2020.106206_b0205","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12967-017-1150-7","article-title":"COX-2 expression positively correlates with PD-L1 expression in human melanoma cells","volume":"15","author":"Botti","year":"2017","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.intimp.2020.106206_b0210","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/0008-5472.CAN-10-3055","article-title":"COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells","volume":"71","author":"Fujita","year":"2011","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.intimp.2020.106206_b0215","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1158\/1078-0432.CCR-14-0635","article-title":"Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity","volume":"20","author":"Mao","year":"2014","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2020.106206_b0220","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.4049\/jimmunol.173.6.4207","article-title":"Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50","volume":"173","author":"Xia","year":"2004","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2020.106206_b0225","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1074\/mcp.M113.029793","article-title":"A quantitative chemical proteomics approach to profile the specific cellular targets of andrographolide, a promising anticancer agent that suppresses tumor metastasis","volume":"13","author":"Wang","year":"2014","journal-title":"Mol. Cell. Proteom.: MCP"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691932541X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757691932541X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:20:49Z","timestamp":1761585649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757691932541X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":45,"alternative-id":["S156757691932541X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106206","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Andrographolide potentiates PD-1 blockade immunotherapy by inhibiting COX2-mediated PGE2 release","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106206"}}